

**Connecticut HB 6669**

**LISRAYA™ (brepocitinib)**

Priovant Therapeutics, Inc. ("Priovant") provides the following information to Connecticut prescribers, as required by Connecticut House Bill 6669 (Public Act No. 23-171).

The pricing information below reflects the Priovant Wholesale Acquisition Cost ("WAC") for the Priovant product: **LISRAYA™**. The WAC represents the published catalogue or list price and may not represent actual transactional prices due to potential discounts, rebates, or other price concessions.

How much a patient will pay will depend on the patient's insurance coverage and available cost assistance programs.

**WAC for LISRAYA™**

| PRODUCT         | NDC          | DOSAGE FORM AND STRENGTH & QUANTITY       | WHOLESALE ACQUISITION COST (WAC) |
|-----------------|--------------|-------------------------------------------|----------------------------------|
| <b>LISRAYA™</b> | 87211-030-30 | Oral Tablet 30 MG – 1 Bottle – 30 Tablets | \$35,000                         |

Information on variation efficacy of the drug marketed to different racial and ethnic groups is currently not available.

For more information on the price disclosure requirements, please contact the Connecticut Commission of Pharmacy at:

The Commission of Pharmacy

450 Columbus Blvd Hartford, CT 06103

Ph. (860) 713-6070 | Fax: (860)-706-1242 | Website: [https://portal.ct.gov/dcp/drug-control-division/commission-of-pharmacy/the-commission-of-pharmacy?language=en\\_US](https://portal.ct.gov/dcp/drug-control-division/commission-of-pharmacy/the-commission-of-pharmacy?language=en_US)

**LISRAYA™** is a trademark of Priovant Therapeutics, Inc.

Copyright© 2026 Priovant Therapeutics, Inc. All rights reserved.

08/27/2026